1.
|
15 p, 2.7 MB |
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
/
Mensali, Nadia (Department of Cellular Therapy. Oslo University Hospital) ;
Köksal, Hakan (Oslo University Hospital) ;
Joaquina, Sandy (Oslo University Hospital) ;
Wernhoff, Patrick (Oslo University Hospital) ;
Casey, Nicholas P. (Oslo University Hospital) ;
Romecín, Paola Alejandra (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Panisello, Carla (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rodríguez, René (Instituto de Salud Carlos III) ;
Vimeux, Lene (Université de Paris) ;
Juzeniene, Asta (Oslo University Hospital) ;
Myhre, Marit R. (Oslo University Hospital) ;
Fåne, Anne (Oslo University Hospital) ;
Castilla-Ramirez, Carolina (Virgen del Rocio University Hospital) ;
Maggadottir, Solrun Melkork (Oslo University Hospital) ;
Duru, Adil Doganay (Nova Southeastern University) ;
Georgoudaki, Anna-Maria (Department of Oncology-Pathology. Karolinska Institutet) ;
Grad, Iwona (Oslo University Hospital) ;
Maturana, Andrés Daniel (Nagoya University) ;
Gaudernack, Gustav (Department of Cancer Immunology. Oslo University Hospital) ;
Kvalheim, Gunnar (Department of Cellular Therapy. Oslo University Hospital) ;
Carcaboso, Angel M. (Institut de Recerca Sant Joan de Déu) ;
De Álava, Enrique (Universidad de Sevilla) ;
Donnadieu, Emma (Université de Paris) ;
Bruland, Øyvind S (University of Oslo) ;
Menendez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Inderberg, Else Marit (Oslo University Hospital) ;
Wälchli, Sébastien (Oslo University Hospital)
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. [...]
2023 - 10.1038/s41467-023-39097-x
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 3375
|
|
2.
|
10 p, 2.6 MB |
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ;
Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ;
Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ;
Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Locatelli, Franco (Sapienza University of Rome) ;
Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ;
Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urdinguio, Rocío G. (Universidad de Oviedo) ;
Fernandez, A.F. (Universidad de Oviedo) ;
Fraga, Mario F. (Universidad de Oviedo) ;
Bar, Diana (The Edmond and Lily Safra Children's Hospital) ;
Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ;
Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ;
Besser, MichalJ. (Tel Aviv University) ;
Avigdor, Abraham (Sheba Medical Center) ;
Jacoby, Elad (Tel Aviv University) ;
Esteller, Manel (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 - 10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445
|
|
3.
|
6 p, 870.5 KB |
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C
/
Notario, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cerdà, Gabriela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Muñoz-Mármol, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Costa, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mate, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. [...]
2023 - 10.3389/fonc.2023.1239000
Frontiers in Oncology, Vol. 13 (october 2023)
|
|
4.
|
16 p, 3.4 MB |
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
/
Dragon, Anna Christina (Hannover Medical School) ;
Beermann, Luca Marie (Hannover Medical School) ;
Umland, Melina (Hannover Medical School) ;
Bonifacius, Agnes (Hannover Medical School) ;
Malinconico, Chiara (Hannover Medical School) ;
Ruhl, Louisa (Hannover Medical School) ;
Kehler, Patrik (Glycotope GmbH) ;
Gellert, Johanna (Glycotope GmbH) ;
Weiß, Lisa (Glycotope GmbH) ;
Mayer-Hain, Sarah (Glycotope GmbH) ;
Zimmermann, Katharina (Hannover Medical School) ;
Riese, Sebastian (Hannover Medical School) ;
Thol, F. (Department of Hematology. Hannover Medical School) ;
Beutel, Gernot (Hannover Medical School) ;
Maecker-Kolhoff, B. (Department of Pediatric Hematology and Oncology. Hannover Medical School) ;
Yamamoto, Felicitas (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blasczyk, Rainer (Hannover Medical School) ;
Schambach, Axel (Hannover Medical School) ;
Hust, Michael (Department of Medical Biotechnology. Technical University of Braunschweig) ;
Hudecek, Michael (Department of Internal Medicine II. University Hospital of Würzburg) ;
Eiz-Vesper, Britta (Hannover Medical School) ;
Universitat Autònoma de Barcelona
Introduction: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy cells, since "on-target/off-tumor" cytotoxicity is usually intolerable. [...]
2023 - 10.3389/fimmu.2023.1219165
Frontiers in immunology, Vol. 14 (2023) , p. 1219165
|
|
5.
|
|
6.
|
11 p, 2.0 MB |
Development of a Novel Anti-CD19 Chimeric Antigen Receptor : A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
/
Castellà, Maria (Hospital Clínic i Provincial de Barcelona) ;
Boronat, Anna (Hospital Clínic i Provincial de Barcelona) ;
Martín-Ibáñez, Raquel (Universitat de Barcelona) ;
Rodríguez, Vanina (Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS) ;
Suñé, Guillermo (Hospital Clínic i Provincial de Barcelona) ;
Caballero, Miguel (Hospital Clínic i Provincial de Barcelona) ;
Marzal, Berta (Hospital Clínic i Provincial de Barcelona) ;
Pérez-Amill, Lorena (Hospital Clínic i Provincial de Barcelona) ;
Martín-Antonio, B. (Hospital Clínic i Provincial de Barcelona) ;
Castaño Cardoso, Julio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Balagué, Olga (Hospital Clínic i Provincial de Barcelona) ;
González-Navarro, Europa Azucena (Hospital Clínic i Provincial de Barcelona) ;
Serra-Pages, Carles (Hospital Clínic i Provincial de Barcelona) ;
Engel, Pablo (Hospital Clínic i Provincial de Barcelona) ;
Vilella, Ramon (Hospital Clínic i Provincial de Barcelona) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Tabera, Jaime (Institut d'Investigació Biomèdica Sant Pau) ;
Canals, Josep M. (Universitat de Barcelona) ;
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Baumann, Tycho (Hospital Clínic i Provincial de Barcelona) ;
Vilarrodona, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Trias, Esteve (Hospital Clínic i Provincial de Barcelona) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urbano-Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Yagüe, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Pérez-Galán, Patricia (Centro de Investigación Biomédica en Red de Cáncer) ;
Rives, Susana (Institut de Recerca Sant Joan de Déu) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). [...]
2019 - 10.1016/j.omtm.2018.11.010
Molecular Therapy. Methods & Clinical Development, Vol. 12 (15 2019) , p. 134-144
|
|
7.
|
14 p, 928.6 KB |
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
/
Sabaté, Mònica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Pérez, Eulàlia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Garcia Doladé, Núria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vidal Guitart, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Carreras Soler, Maria Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Farriols Danés, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Braña, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Carles, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Morales-Barrera, Rafael (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Muñoz Couselo, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Data related to adverse drug reactions (ADRs), specifically immune-related adverse events (irAEs), in long-term treatment with immunotherapy in real-world practice is scarce, as is general information regarding the management of ADRs. [...]
2022 - 10.3389/fmed.2022.891179
Frontiers in Medicine, Vol. 9 (august 2022)
|
|
8.
|
11 p, 529.4 KB |
Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial
/
Martin-Broto, J. (Universidad de Sevilla) ;
Hindi, Nadia (Universidad de Sevilla) ;
Grignani, G. (Candiolo Cancer Institute) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Redondo, A. (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Stacchiotti, S. (Istituto Nazionale Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
D'Ambrosio, L. (Candiolo Cancer Institute) ;
Gutierrez, A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Perez-Vega, H. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Encinas-Tobajas, V. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Álava, Enrique (Universidad de Sevilla) ;
Collini, Paola (Istituto Nazionale Tumori) ;
Peña-Chilet, M. (Hospital Virgen Del Rocio) ;
Dopazo, J. (Hospital Virgen Del Rocío) ;
Carrasco-Garcia, I. (Universidad de Sevilla) ;
Lopez-Alvarez, M. (Universidad de Sevilla) ;
Moura, D.S. (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. [...]
2020 - 10.1136/jitc-2020-001561
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (17 2020) , p. e001561
|
|
9.
|
10 p, 1.1 MB |
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
García-Martínez, E. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martinez, M. (Hospital del Mar (Barcelona, Catalunya)) ;
Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia) ;
Rodriguez-Abreu, D. (C.H.U. Insular-Materno Infantil de Gran Canaria) ;
Alvarez, R. (Hospital Virgen de la Salud (Toledo)) ;
Arance, Ana (Hospital Clínic i Provincial de Barcelona) ;
Berrocal, A. (Hospital General Universitario de Valencia) ;
de la Cruz Merino, Luis (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. [...]
2020 - 10.1007/s12094-019-02273-x
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 213-222
|
|
10.
|
13 p, 423.1 KB |
Pharmacological cancer treatment and venous thromboembolism risk
/
Muñoz Martín, A.J. (Hospital General Universitario Gregorio Marañón) ;
Ramírez, S.P. (Hospital General Universitario Gregorio Marañón) ;
Morán, L.O. (Hospital General Universitario Gregorio Marañón) ;
Zamorano, M.R. (Universidad Complutense de Madrid) ;
Benéitez, M.C.V. (Universidad Complutense de Madrid) ;
Salcedo, I.A. (Hospital General Universitario Gregorio Marañón) ;
Escobar, I.G. (Hospital General Universitario de Ciudad Real) ;
Soria Fernández, José Manuel (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. [...]
2020 - 10.1093/EURHEARTJ/SUAA004
European heart journal supplements, Vol. 22 (2020) , p. C2-C14
|
|